SUTRO BIOPHARMA, INC.(STRO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

SUTRO BIOPHARMA, INC. (STRO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STRO at 15.3/100 on a 32-signal composite quality model, placing it at rank #2,854 of 2,961 stocks — the bottom half of the AI-ranked universe. STRO scores in the top quartile across institutional flow (92.7). Areas of concern include balance sheet strength (1.6) and free cash flow (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SUTRO BIOPHARMA, INC. reports quarterly revenue of $9.8M, net income of $-38.5M. Top institutional holders of STRO by reported 13-F value include PERCEPTIVE ADVISORS, BVF, Affinity Asset Advisors, based on the most recent SEC filings. STRO trades on the Nasdaq exchange and files with the SEC under CIK 1382101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUTRO BIOPHARMA, INC. directly from SEC EDGAR.